HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New ...
LOS ANGELES, CA - March 10, 2026 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint ...
HeartBeam, Inc. BEAT shares are trading higher Tuesday after the company announced a strategic partnership with Mount Sinai to accelerate the joint development and validation of next-generation AI-ECG ...
Stocktwits on MSN
HeartBeam and Mount Sinai announce strategic AI collaboration to bring clinical-grade heart monitoring into the home
Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk ・Combines Mount Sinai’s world-class AI and ...
HeartBeam (Nasdaq:BEAT) announced today that it entered into a strategic collaboration with the Icahn School of Medicine at Mount Sinai.
Researchers at King's College London have shown that a widely used cardiac arrest risk score can be applied before patients ...
InvestorsHub on MSN
HeartBeam partners with Mount Sinai to advance AI-powered ECG technology
HeartBeam (NASDAQ:BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai aimed at accelerating the development and clinical validation of next-generation artificial ...
The architecture of a multimodal system depends on the coordination of diverse hardware and software components into a single ...
If you’re a Whoop member, you can expect to see two new women’s health updates for both hormonal insights and blood panels.
Footage of Vladimir Putin coughing and struggling to catch his breath have sparked fresh concern for the Russian president's health. On Saturday, March 7, The Kremlin mistakenly posted an unedited ...
Barclays 28th Annual Global Healthcare Conference March 10, 2026 10:30 AM EDTCompany ParticipantsThierry Pieton - Executive VP ...
Founded in 2009 by Anand Sivaraman, Remidio builds hardware and AI tools that enable early detection of eye diseases and, increasingly, systemic health risks through retinal analysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results